Candel Therapeutics Inc (CADL) - Total Liabilities
Based on the latest financial reports, Candel Therapeutics Inc (CADL) has total liabilities worth $63.89 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Candel Therapeutics Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Candel Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See Candel Therapeutics Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Candel Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Candel Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Naphtha
TA:NFTA
|
Israel | ILA3.16 Billion |
|
Haier Smart Home Co Ltd
F:690D
|
Germany | €165.78 Billion |
|
Velesto Energy Bhd
KLSE:5243
|
Malaysia | RM350.67 Million |
|
Sunplus Technology Co Ltd
TW:2401
|
Taiwan | NT$3.41 Billion |
|
Hingham Institution for Savings
NASDAQ:HIFS
|
USA | $4.06 Billion |
|
Royce Micro Cap Closed Fund
NYSE:RMT
|
USA | $20.93 Million |
|
EPC Groupe
PA:EXPL
|
France | €314.97 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Candel Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CADL company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 28.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Candel Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Candel Therapeutics Inc (2019–2025)
The table below shows the annual total liabilities of Candel Therapeutics Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $73.27 Million | +80.75% |
| 2024-12-31 | $40.54 Million | +42.46% |
| 2023-12-31 | $28.46 Million | -7.63% |
| 2022-12-31 | $30.80 Million | +22.89% |
| 2021-12-31 | $25.07 Million | -59.47% |
| 2020-12-31 | $61.84 Million | +14.66% |
| 2019-12-31 | $53.94 Million | -- |
About Candel Therapeutics Inc
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of … Read more